O'Reilly Automotive rises after Raymond James upgrades to 'outperform'
ReutersNov 5, 2025 3:06 PM
Shares of O'Reilly Automotive ORLY.O up nearly 2% at $95 in early trading
Raymond James raises rating to "outperform" from "market perform," maintains PT at $105
Brokerage says co is expected to grow strongly in 2025–26, driven by pricing tailwind, robust demand, store expansion and solid financials
Says expansion in Mexico and Canada could fuel long-term growth
25 of 31 brokerages rate the stock "buy" or higher, 6 "hold"; their median PT is $112 - data compiled by LSEG
Including session moves, shares up 20.8% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Tesla’s 2025 Shareholder Meeting Showdown: Musk’s Leadership and Tesla’s Crossroads
TradingKey - Tesla (TSLA), the electric vehicle leader, will hold its 2025 Annual Shareholder Meeting on November 6. Dubbed by CEO Elon Musk as a moment that will “decide Tesla’s future and shape the world’s,” the event centers on one pivotal question: Will shareholders approve Musk’s proposed $1 TTradingKey
5 hours ago
What Drove the 'Black Tuesday' Sell-Off? Three Key Factors Behind the U.S. Stock Plunge
TradingKey - On November 4, 2025, U.S. markets suffered a sudden and sharp selloff — dubbed “Black Tuesday” — with the Nasdaq posting its largest single-day drop in a month. The rout unfolded amid growing economic and political instability, as a record-long government shutdown worsened systemicTradingKey
8 hours ago
IonQ Stock Price Skyrockets 300% in a Year, But Recently Drops 30%—Is IonQ Still a Buy?
Is IonQ worth buying? With a recent decline of nearly 30% over the past month, is now the time to buy? How much further could IonQ's stock rise?TradingKey
9 hours ago
Novo Nordisk Q3 Earnings Preview: New CEO, Board Overhaul — Can the U.S. Weight-Loss Market Turn Around?
TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.TradingKey
Tue, Nov 4
Palantir Q3 2025 Earnings: Blowout Performance Can’t Hide an AI Bubble， Four Growing Risks Behind a Nearly 1,000x Valuation
TradingKey – After the close of trading on November 4, “AI application King” Palantir Technologies (PLTR) reported its third-quarter earnings for fiscal year 2025. Despite a blowout quarter, surging top-line growth, and a flood of commercial orders, the stock plunged in after-hours trading.TradingKey
Tue, Nov 4
